Key Highlights

  • BioNTech (NASDAQ:BNTX) was listed to report third quarter 2026 results before the open on November 3, 2026, with a consensus EPS estimate of 0.76 per share and a Market Value of about USD 22.25 billion.
  • Second quarter Revenue was EUR 105.6 million against EUR 260.8 million a year earlier, with an IFRS net loss of EUR 820.8 million, or EUR 3.24 per share, on lower COVID-19 Vaccine demand.
  • Full-year 2026 revenue guidance was cut to EUR 1.6 billion to EUR 1.9 billion from EUR 2.0 billion to EUR 2.3 billion, citing softer vaccine Demand in Germany and a milestone no longer expected.
  • The company expects to recognise EUR 613 million of Bristol Myers Squibb collaboration revenue in the third quarter, and held EUR 16.6 billion of cash and security investments at June 30, 2026.

What Investors Expect From the Third Quarter

This is an upcoming event, not a reported result. Management said most 2026 revenue falls in the second half, specifically the third quarter, which includes the EUR 613 million from Bristol Myers Squibb. If other revenue resembled the EUR 105.6 million of the second quarter, the total would be about EUR 719 million, simple arithmetic on published figures. That is why a positive consensus of 0.76 per share, whose currency basis could not be confirmed, contrasts with a second quarter adjusted loss of EUR 2.22 per share. The third quarter will largely decide whether BioNTech (NASDAQ:BNTX) reaches its revised revenue range, because the guidance leaves little room for a second consecutive quarter of low collaboration income.

Pipeline, Costs and Capital Returns

Adjusted R&D guidance was lowered to EUR 2.0 billion to EUR 2.3 billion from EUR 2.2 billion to EUR 2.5 billion, and adjusted SG&A stays at EUR 700 million to EUR 800 million, with CureVac consolidated into costs. The lead program, pumitamig, which BioNTech (NASDAQ:BNTX) develops with Bristol Myers Squibb, has seven pivotal trials running, five of them started in the first half. The DYNASTY-Breast02 primary analysis is expected in the fourth quarter. A buyback of up to USD 1.0 billion runs to May 6, 2027, and Guido Oelkers is due to become chief executive by February 1, 2027. Share repurchases so far total 1,693,056 ADSs for EUR 131.8 million.

Bull Case, Bear Case and the Size of the Move

No options-implied move was found. Each 5 percent move on a USD 22.25 billion market value is about USD 1.1 billion, simple arithmetic. A bull case is recognition of the EUR 613 million, other revenue above the second quarter level and a reiterated guidance range, which would shift attention back to pipeline readouts for BioNTech (NASDAQ:BNTX). A bear case is a revenue shortfall that puts the EUR 1.6 billion floor at risk, higher costs or a delayed readout. Pfizer reports the same morning, and Moderna reports on November 6, 2026, so vaccine peers may add noise to the reaction on the day, as the group trades on shared themes.

Where Things Stand

The answer is BioNTech (NASDAQ:BNTX): the cash pile is large, but revenue is lumpy and the third quarter carries the Bristol payment that supports the reduced guidance. The balance of evidence is mixed, with heavy losses, falling vaccine sales and a CEO transition set against EUR 16.6 billion of cash, a buyback and a broad late-stage oncology pipeline. The next catalysts are the November 3 report and the DYNASTY-Breast02 analysis in the fourth quarter.